UNSPSC 51144117: Etilamfetamine or ethylamphetamine or n-ethylamphetamine

This classification denotes a cns stimulant with the molecular formula C11H17N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 022YON1XMX, chemically known as phenethylamine, n-ethyl-.alpha.-methyl-, hydrochloride but more generally known as etilamfetamine, which bears US NIH Compound Identifier 9982. European Medicines Agency schedules Etilamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12434MIG.

UNSPSC 51144117 Etilamfetamine or ethylamphetamine or n-ethylamphetamine is a Commodity code that shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code's technical name refers to a controlled stimulant precursor compound, yet the three recent opportunities tagged to it involve naloxone distribution, direct-to-manufacturer prescription programs, and generic pharmaceutical supply — none of which are chemically or functionally related to the coded substance. State and local procurement offices appear to have applied this code incorrectly to general pharmaceutical and health-services procurement. The issuing bodies include a county health department (Seminole County, Florida), a state health agency (Texas Health and Human Services Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, with Oregon participation). The work being solicited is actual drug procurement and distribution: naloxone and drug deactivation systems for opioid overdose response, direct contracting between state health plans and pharmaceutical manufacturers to bypass traditional pharmacy benefit managers, and generic multistate pharmaceutical supply through authorized wholesalers.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the most concrete procurement visible in the MMCAP RFP (due March 26, 2026) for generic and OTC products distributed across multiple state and local health facilities, and Seminole County's IFB (due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas HHS Commission issued an RFI on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment capacity, signaling emerging state interest in supply-chain redesign. The code's recent activity does not reflect its intended scope; firms pursuing state and local pharmaceutical procurement should monitor actual pharmaceutical-family codes rather than rely on this Commodity code as a sourcing signal.